DELFEN (nonoxynol-9) by Personal Genomics. Approved for contraception. First approved in 1963.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
DELFEN is a nonoxynol-9 vaginal aerosol contraceptive and microbicide approved in 1963 for prevention of pregnancy and HIV infections. It is a spermicidal surfactant that disrupts sperm cell membranes and inactivates enveloped viruses through detergent action. The product represents an older, non-hormonal approach to contraception with dual-indication potential.
As a 60+ year old product approaching loss of exclusivity with minimal reported spending, DELFEN likely operates with a lean, defensive brand team focused on legacy market maintenance rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
A Study of Nonoxynol-9 (N-9) and HIV Infection
DELFEN offers minimal career advancement opportunity; linked job count is zero, reflecting its legacy status and niche market position. Professionals assigned to this product should view it as a portfolio-sustaining role rather than a growth engine or skill-building opportunity.
Worked on DELFEN at Personal Genomics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.